GLG News by Oncologists who Treat Hematologic Malignancies (US)

ESA's shorten survival when the hemoglobins are elevated to "normal" levels. The entire subject will be re-reviewed by the FDA in the next few months.

Bayer's Nexavar and Pfizer's Sutent appear to have slight activity in 2 variants of RCC that make up about 10% of all kidney cancers.

Medical oncologists have "maxed out" on  chemo combinations in lung cancer.  It is clear that biologic agents need to be incorporated into our treatment regimens in order to move forward. Erbitux is safer and can be used in a broader population of lung cancer patients than Avastin.

"Nothing ventured, nothing gained." The patients were not treated uniformly thus the results are completely inconclusive.

Avastin + chemo in metastatic breast cancer improves progression but not overall survival. No wonder the FDA rejected it in breast cancer BUT...

Revlimid appears to deliver rather impressive results Re: transfusion independence (or decreased frequency) in Low and intermediate 1 risk non 5Q- MDS.

Yada Yada Yada Hemoglobins need to be < 10 grams in order to give Epo.

Roche received approval for Avastin plus interferon (IFN) in advanced RCC

A phase I/II trial of a heat shock protein 90 (Hsp90) inhibitor is being tested in patients with and without an Epidermal Growth Factor Receptor (EGFR) mutation that "sensitizes" the lung cancer cells to some targeting agents.

A novel antibody, ALX-0081, that is well tolerated nd is directed against von Willebrand Factor (anti-vWF), that is strongly implicated in taking part in acute coronary events and conclusively responsible for the disastrous outcomes of thrombotic thrombocytopenic purpura (TTP).